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Abstract
Purpose Chemotherapy is the mainstay treatment for
advanced non-small cell lung cancer (NSCLC). Geﬁtinib,
an epidermal growth factor receptor—tyrosine kinase
inhibitor (EGFR-TKI), has been recently shown to be
effective as a ﬁrst-line treatment in Asian patients with
advanced NSCLC, especially for those with favourable
clinical features such as female, non-smoker and adeno-
carcinoma. However, resistance to geﬁtinib ensues invari-
ably and there is little evidence as for the effectiveness of
subsequent salvage treatment. The purpose of this study is
to evaluate the efﬁcacy of erlotinib, another EGFR-TKI,
after failed ﬁrst-line use of geﬁtinib.
Method Retrospective review of NSCLC patients with
favourable clinical features who received geﬁtinib as ﬁrst-
line treatment and subsequent salvage treatment with
erlotinib.
Results A total of 21 patients with NSCLC were included
in the study. Among them, 18 (85.7%) patients had disease
control with geﬁtinib and 12 (57.1%) patients with salvage
erlotinib. There was an association between the disease
control with geﬁtinib and erlotinib (p = 0.031). The dis-
ease control rate of erlotinib was independent of the che-
motherapy use between the two EGFR-TKIs.
Conclusion For NSCLC patients with favourable clinical
features, erlotinib was effective in those who had prior
disease control with ﬁrst-line geﬁtinib.
Keywords Non-small cell lung cancer  Geﬁtinib 
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Introduction
Lung cancer, predominantly non-small cell carcinoma
(NSCLC), has been a major cause of cancer deaths
worldwide [1] mostly related to its advanced stages upon
presentation. Platinum-based chemotherapy has become
the mainstay systemic treatment for advanced NSCLC
with modest improvement in overall survival and quality
of life [2], at the expense of moderate to severe toxicities
[3]. In recent years, selective epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) has
emerged as an alternative treatment option for advanced
NSCLC with distinct mechanism of action and safety
proﬁle. Both erlotinib and geﬁtinib, as prototypes of
EGFR-TKI, have demonstrated clinical efﬁcacy in the
second- or third-line treatment of NSCLC, especially
among never-smokers, females, East Asians, and adeno-
carcinoma cell type. [4–7].
With the favourable toxicity proﬁle of EGFR-TKI, there
have been great interests to bring it upfront in the ﬁrst-line
treatment of advanced NSCLC. Geﬁtinib used in the ﬁrst-
line setting has been reported with promising results in
Asian countries [8, 9]. Moreover, a multicentre phase III
randomised clinical trial has recently suggested that geﬁ-
tinib might be a good option for ﬁrst-line treatment of
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superior clinical efﬁcacy and tolerability compared to
standard chemotherapy [10]. However, subsequent resis-
tance to geﬁtinib is inevitable even among the initial good
responders, mostly related to acquired EGFR mutation
(T790M) or c-met ampliﬁcation [11, 12].
Large-scale phase III clinical trials have demonstrated
survival beneﬁt with erlotinib but not geﬁtinib as second-
or third-line treatment of advanced NSCLC, suggesting
pharmacological differences between the two EGFR-TKIs
[4, 7]. It would be logical to try erlotinib in case of geﬁtinib
failure, especially among those highly selected patient
population with anticipated favourable response to EGFR
inhibition. Therefore, we conducted a retrospective review
of our single institutional experience of salvage erlotinib
treatment in patients with advanced NSCLC after failure to
ﬁrst-line geﬁtinib.
Materials and methods
Patient identiﬁcation and data collection
Eligible patients, all Chinese, had histologically or cyto-
logically conﬁrmed NSCLC who received treatment with
geﬁtinib as ﬁrst-line and erlotinib as subsequent salvage
therapy from January 2004 to December 2008 in the
Department of Medicine at Queen Mary Hospital, an
University-afﬁliated teaching hospital in Hong Kong.
Clinical data were collected retrospectively, including age,
sex, performance status on diagnosis (Eastern Cooperative
Oncology Group performance status [ECOG PS]), smoking
history, staging of disease, EGFR mutation, systemic che-
motherapy, radiotherapy, best overall tumour responses,
geﬁtinib or erlotinib-related adverse reactions, reasons of
stopping EGFR-TKI, and mortality until 31st December
2008. The study protocol was approved by the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster and conducted
according to the Declaration of Helsinki. The primary aim
was to assess the disease control rates of patients who
received erlotinib in the salvage setting after failure to ﬁrst-
line geﬁtinib. The secondary outcome was to identify
predicting factors for response to salvage treatment with
erlotinib.
Response evaluation
According to institutional practice, all patients were regu-
larly followed up every 4 weeks (±1 week) with imaging
studies (chest X-ray or computed tomography [CT] where
appropriate) during treatment with EGFR-TKIs. The best
overall tumour responses (complete response [CR], partial
response [PR], stable disease [SD] and progressive disease
[PD]) during the course of different treatment modalities
were based on review of medical records and imaging
studies available, according to RECIST criteria [13]. In the
case of stable disease, measurements must have met the
stable disease criteria at least once after study entry at a
minimum interval (in general, not less than 6–8 weeks)
[13]. Responses to EGFR-TKIs were evaluated at least
4 weeks after the initiation of treatment. Disease control
(DC) was deﬁned as a lack of PD and clinical improvement
or stability, as assessed by the attending physicians, and
continuation of drug treatment for at least 8 weeks. The
treatment with EGFR-TKIs would be stopped at the time of
documented worsening of existing lesions or emergence of
new lesions, which was regarded as PD. Overall survival
was evaluated from the initiation of geﬁtinib therapy to the
date of death or study cut-off on 31st December 2008.
Toxicity evaluation
Toxicity proﬁle of EGFR-TKI was assessed by reviewing
medical records, including skin rash, diarrhoea, liver tox-
icity, and radiological evidence of interstitial pneumonitis.
Severity of adverse reactions was determined according to
the need of dosage reduction or discontinuation of EGFR-
TKI.
Statistical analysis
Continuous data were expressed as mean ± SD and cate-
gorical data were expressed as percentage. Comparisons
between two groups were performed with Student’s t-test
for continuous variables and Fisher’s exact test for cate-
gorical variables. The relationship between the disease
control rate of geﬁtinib and erlotinib was explored using
McNemar’s test. Survival analysis was conducted with
Kaplan Meier analysis and log-rank test. A p-value of less
than 0.05 was considered signiﬁcant. All statistical tests
were conducted using the computer software SPSS version
16.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical and epidemiological characteristics
Sixty-eight patients with NSCLC who received both geﬁ-
tinib and erlotinib were screened. Twenty-one Chinese
patients (19 women; mean age 67.9 ± 8.1 years) received
geﬁtinib as the ﬁrst-line treatment and erlotinib as salvage
therapy, with or without systemic chemotherapy in
between the EGFR-TKIs. All of them were never smokers
except one who had quitted for 40 years with less than 10
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adenocarcinoma (90%) and in advanced stage (61.9% stage
IV) on presentation. EGFR mutation tests were available in
four patients, in whom three of them were positive for
point mutation in exon 21 (L858R and L861Q) and one
was negative. At the time of initiation of geﬁtinib treat-
ment, most of the patients were in good performance status
([90% in ECOG 0 or 1). Geﬁtinib was prescribed at
standard dosage of 250 mg daily and erlotinib at 150 mg
daily. Erlotinib was used as second-line treatment in 13
(62%) patients immediately after failure to geﬁtinib
(Table 1).
Tumour response
Disease control was achieved in 18 patients (85.7%) and 12
patients (57.1%) with geﬁtinib and erlotinib as ﬁrst-line and salvage therapy, respectively. All the 12 patients who
achieved disease control with erlotinib were having SD as
their best response. There is a signiﬁcant association
between the occurrence of disease control to geﬁtinib in the
ﬁrst-line and that to erlotinib as salvage treatment
(p = 0.031, Fig. 1). For those 18 patients who had prior
disease control with geﬁtinib, 12 patients (66.7%) attained
disease control with erlotinib. For those three patients
whose disease could not be controlled with geﬁtinib, all of
them did not respond to erlotinib. The disease control with
erlotinib was independent of age, gender, duration of gef-
itinib treatment and the use of chemotherapy between the
two EGFR-TKIs. The median overall survival of this group
was 25.2 months (interquartile range 29.6 months). Five
patients (23.8%) received chemotherapy after the failure of
the two EGFR-TKIs. Four of them had progressive disease
shortly after 1–4 courses of chemotherapy (pemetrexed
[n = 2], gemcitabine/carboplatin/bevacizumab [n = 1],
sequential docetaxel and gemcitabine [n = 1]) and the
remaining one had partial response to six cycles of gem-
citabine/carboplatin doublet. Patients were found to have
signiﬁcantly shorter overall survival if disease control
could not be achieved with the use of erlotinib as salvage
therapy, 10.3 versus 40.0 months (p = 0.002, Fig. 2). The
median progression-free survival for geﬁtinib and erlotinib
was 23.7 weeks (interquartile range 31.5 weeks) and
14.9 weeks (interquartile range 16.1 weeks), respectively
(Fig. 3).
Toxicity
One patient had geﬁtinib withheld for 1.5 months because
of skin toxicity and subsequently tolerated well after
resumption until disease progression. She had no adverse
reaction with the subsequent use of erlotinib. None of the
patients had treatment terminated because of severe tox-
icity from EGFR-TKIs.
Table 1 Characteristics of 21 Chinese patients with non-small cell
lung cancer (NSCLC) treated with geﬁtinib as ﬁrst-line and erlotinib
as salvage therapy
Characteristic n %
Age, years
Mean ± SD 67.9 ± 8.1
Range 50–83
Sex
Female 19 90.5
Male 2 9.5
Smoking history
Never smoker 20 95.2
Ex-light smoker 1 4.8
Cell type
Adenocarcinoma 19 90.4
Large cell carcinoma 1 4.8
NSCLC 1 4.8
EGFR mutation
Not done 17 80.9
Positive 3 14.3
Negative 1 4.8
Stage
IIIb 8 38.1
IV 13 61.9
ECOG performance status
0 6 28.6
1 13 61.9
2 2 9.5
Chemotherapy between two EGFR-TKIs
Yes 8 38.1
No 13 61.9
EGFR epidermal growth factor receptor, ECOG Eastern Cooperative
Oncology Group, TKI tyrosine kinase inhibitor
Fig. 1 Relationship between disease control to geﬁtinib and erlotinib.
There was signiﬁcant association between the occurrence of disease
control to geﬁtinib and that to erlotinib (McNemar test p = 0.031).
DC disease control, DP disease progression
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Although recent clinical trials have provided emerging
evidence for geﬁtinib as ﬁrst-line treatment for patients
with NSCLC, there is a lack of clinical data exploring the
role of erlotinib as subsequent therapy after failure to
geﬁtinib. In this retrospective study of a highly selected
subgroup (Chinese, nonsmokers, adenocarcinoma and
females) of advanced NSCLC who responded favourably
to geﬁtinib in the ﬁrst-line setting, salvage treatment with
erlotinib could attain a disease control rate of 66.7%,
though only stable disease was achieved as the best overall
response. Most patients (ECOG 0 or 1 in[90%) in the
current study were suitable candidates for systemic che-
motherapy as an alternative ﬁrst-line treatment. Nonethe-
less, based on the promising results from recent trials,
geﬁtinib would undoubtedly be considered as a superior
ﬁrst-line treatment for advanced NSCLC in patients with
favourable clinical variables (Asian ethnicity, non-smoker
or ex-light smoker, adenocarinoma and female) or presence
of sensitising EGFR mutations in tumour samples [8–10].
Therefore, the encouraging result of salvage erlotinib after
failure to ﬁrst-line geﬁtinib in advanced NSCLC would
certainly be of clinical interest.
The exceptionally high disease control rate of ﬁrst-line
treatment with geﬁtinib (85.7%) in our study is likely to be
related to selection bias in a non-trial setting. In clinical
practice, geﬁtinib is mostly chosen to be the ﬁrst-line
treatment in an enriched patient population with favourable
predictors for good response, preferably including EGFR
sensitising mutations. One of the limiting factors for testing
EGFR mutation status is the lack of tissue availability.
EGFR was only tested in 20% of our patients as it was not
considered as a prerequisite during the study period and the
aforementioned clinical variables would provide a close
approximation. Although there was a lack of clinical data
to support the use of erlotinib as a salvage treatment after
failure to ﬁrst-line geﬁtinib, this approach of treatment was
mostly adopted for patients who had demonstrated good
response to previous geﬁtinib treatment. Otherwise, alter-
native treatment approach with systemic chemotherapy or
best supportive care would be offered. Interestingly, in this
highly selected NSCLC patient population with prior dis-
ease control from geﬁtinib, subsequent treatment with the
same class of targeted therapy, namely erlotinib, could also
result in disease control in 66.7% (12/18) of patients. The
use of chemotherapy before treatment with erlotinib, or the
presence of ‘‘EGFR-TKI-free’’ period, apparently was not
a pre-requisite for response to salvage erlotinib treatment in
our study cohort.
Ever since the ﬁrst report of a patient with advanced
NSCLC who responded to erlotinib after failure of geﬁti-
nib, there have been several anecdotal case reports [14–18],
retrospective case series [19–21] and three phase II clinical
trials [22–24] on this approach with conﬂicting results.
Most of the case series and clinical trials reported the
experience of using geﬁtinib in the second- or third-line
setting, with erlotinib being used in at least the third-line
setting. Two phase II clinical trials on advanced NSCLC
have reported encouraging disease control rates (28.6 and
62.5%) with the use of salvage erlotinib in patients with
previously high disease control rates to geﬁtinib (47.6 and
100%, respectively) [23, 24]. However, another phase II
clinical trial has only demonstrated a disease control rate of
8.7% with salvage erlotinib despite previous good response
to geﬁtinib (disease control rate 73.9%) [22]. Heterogene-
ity of the study populations might account for the con-
ﬂicting results.
An acquired EGFR mutation (T790M) has been reported
to occur upon failure of geﬁtinib and is also predictive of
resistance to erlotinib [11, 25]. However, the acquired
Fig. 3 Kaplan–Meier plot of progression-free survival with a median
of 14.9 weeks for patients treated with salvage erlotinib
Fig. 2 Kaplan–Meier plot of overall survival. Median survival was
40.0 months (95% conﬁdence interval: 13.6–66.4) for erlotinib
responder and 10.3 months (95% conﬁdence interval: 4.26–16.3)
for erlotinib non-responder (p = 0.002)
1026 Cancer Chemother Pharmacol (2010) 65:1023–1028
123resistance is not completely explained by the T790M
mutation in all cases [26]. The presence of heterogenous
malignant clones with different EGFR mutation status may
confer differential sensitivity to the two EGFR-TKIs [27].
Also, the different treatment efﬁcacy between the two
EGFR-TKIs has been proposed to be related to drug
pharmacokinetics [28], with geﬁtinib given at largely sub-
maximal tolerated dose (MTD) in contrast to erlotinib at
MTD. Erlotinib is less susceptible than geﬁtinib to
metabolism by the cytochrome-P450 pathway with lower
clearance rate, thus able to inhibit the activity of wild-type
EGFR at lower concentration than geﬁtinib [29, 30]. Loss
of acquired resistance after a signiﬁcant ‘‘TKI-free inter-
vals’’ or chemotherapy given during the TKI free interval
can also potentially result in reduction of TKI-resistant
clones [31].
In conclusion, erlotinib might be considered as a salvage
treatment for highly selected patients with advanced
NSCLC who demonstrated initial disease control with ﬁrst-
line geﬁtinib, irrespective of the use of chemotherapy in
between the two EGFR-TKIs. A large prospective ran-
domized control trial, with EGFR mutation studies, is
warranted to conﬁrm our observations.
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